Ambee Pharmaceuticals PLC reported a 40% year-on-year decline in earnings per share (EPS) in the first quarter of FY27, reflecting continued pressure on its profitability.
The company’s EPS stood at Tk0.30 for July-September 2026, down from Tk0.50 in the same period of the previous fiscal year, according to its unaudited financial statements disclosed through the Dhaka Stock Exchange (DSE) today (16 November).
Its annual earnings also weakened, with EPS falling 52% to Tk1.06 in FY26 from Tk2.21 in FY25.
Despite the decline in earnings, the company’s net operating cash flow per share (NOCFPS) improved to Tk25.82 in FY26 from Tk9.06 a year earlier. Its net asset value (NAV) per share also edged up to Tk13.53 as of 30 June 2026, from Tk13.47 a year earlier.
In the first quarter of FY27, NOCFPS remained negative at Tk6.72, although the deficit narrowed from Tk9.28 in the corresponding period a year earlier. NAV per share rose further to Tk13.83 as of 30 September 2026.
Meanwhile, the company’s board has recommended a 10% cash dividend for FY26. The record date is 2 December, and the annual general meeting (AGM) is scheduled for 23 December at 11am through a digital platform.
Ambee Pharmaceuticals, established in 1976, began commercial production in 1978. Its factory and head office are in Dhaka’s Tejgaon industrial area. The company manufactures tablets, capsules, liquid medicines, gels and injectables for the domestic market and exports to Myanmar.
Listed on the stock market in 1986, the company has a paid-up capital of Tk2.40 crore. DSE data show that sponsors and directors held 77.25% of its shares as of 31 October 2026, while institutional investors owned 5.57% and general investors 17.18%. Foreign and government investors held no shares.
Institutional ownership declined from 8.37% as of 30 June 2025, while general investors’ holdings increased. The company’s shares closed at Tk702.30 on the DSE today.
